Skip to Main Content

Paper Details

Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).
Circ Genom Precis Med
9
2018
CHD9, G, GHR, Genetic Variants, Hypertensive, PEAR, Patients, Plasma Renin, Plasma renin, RNA sequencing, SNN, SNN-TXNDC11 gene region, SNPs, TXNDC11, XIRP2, ancestry, atenolol, hydrochlorothiazide, principal components, rs1802409, rs3784921, single-nucleotide polymorphisms
Author NameAffiliation
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Nihal El RoubyDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Kent R BaileyDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Eric BoerwinkleDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Eric BoerwinkleDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Steven E SchererDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Steven E SchererDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Wolfgang Sad??eDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Stephen T TurnerDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Rhonda M Cooper-DeHoffDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics (C.W.M., Department of Pharmaceutical Outcomes and Policy (C.D.), Department of Pharmaceutics, Genetics Institute (A.C.C.S., College of Liberal Arts and Sciences (W.M.), College of Medicine (J.G.G.), University of Florida, Gainesville School of Pharmacy, College of Health Professions, Pacific University, Faculty of Pharmacy, Ain Shams University, Mayo Clinic, Institute of Molecular Medicine, University of Texas Health Science Center, University of Chicago, Center for Pharmacogenomics (A.W.) and Department of Cancer Biology and Genetics, College of Medicine (W.S.), Ohio State University, Baylor College of Medicine
  • 1 - 12

Datasets